Polaris Market Research presents its latest market research report, titled Blood Plasma Market Size, Share, Trends, Industry Analysis Report, 2026-2034. It is a comprehensive market research report analyzing the fast-evolving blood plasma market. The report offers insight into the current market landscape, drivers for growth, emerging trends, competitive dynamics, and future scope for growth. The study is a combination of qualitative and quantitative analysis, giving insights about the size of the market, segments, regional performance, and industry developments. By going through the report, stakeholders can get an in-depth overview of the blood plasma market and its outlook during the forecast period.

Blood Plasma Market Key Takeaways

• The blood plasma market size was valued at USD 34.09 billion in 2025.
• The market is estimated to reach USD 63.74 billion by 2034.
• The market is projected to witness a CAGR of 7.20% from 2026 to 2034.
• The immunoglobulin segment held 48.0% of the market share in 2025.
• The hemophilia application segment is likely to grow at a 35.0% CAGR during the forecast period.
• The North America region held 45.0% of market share in 2025.
• The Asia Pacific region is expected to grow at a CAGR of 8.50% from 2026 to 2034.

What is Blood Plasma Market?

Blood plasma is the liquid portion of blood that carries red and white blood cells, platelets, salts, enzymes, proteins, and antibodies throughout the body. It is used to treat burn, shock, and trauma patients, along with individuals suffering from clotting-factor deficiencies or severe liver disease. Pharmaceutical companies process donated plasma into therapies for bleeding disorders and immune deficiencies, supporting demand for blood plasma, immunoglobulins, albumin, and related plasma-derived products worldwide.

Market Dynamics

The report examines the key market dynamics influencing the growth and development of the blood plasma market. It analyzes the market drivers, market opportunities, market trends, and restraints that might impact the growth of the market.

Key Market Driver: Rising Demand for Plasma-Derived Therapies

Growing incidence of chronic and rare conditions such as hemophilia, immunodeficiency disorders, and autoimmune diseases is lifting demand for plasma-derived therapies. An aging global population that is more susceptible to conditions requiring such therapies adds to this demand. Improvements in the safety and efficacy of plasma collection and processing, alongside rising awareness among clinicians and patients, continue to widen the use of immunoglobulins, albumin, and clotting-factor products across healthcare systems.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/global-blood-plasma-market 

Market Opportunity: Expanding Healthcare Spending in Emerging Economies

Rising healthcare expenditure in countries such as India and Thailand is opening a lucrative opportunity for plasma product manufacturers. As hospital infrastructure improves and access to specialty care widens, demand for plasma-derived treatments in these markets is set to accelerate, giving established players room to expand distribution networks and build new collection and fractionation capacity in underserved regions.

Emerging Market Trend: Advances in Plasma Collection and Fractionation Technology

Continuous improvement in plasma fractionation, purification, and pathogen-reduction methods is enhancing the safety and consistency of plasma-derived products. These advances are helping manufacturers expand production capacity while meeting increasingly strict regulatory requirements, and they are supporting the development of new indications for plasma-based therapies across immunology, neurology, and critical care.

Market Challenge: High Cost and Rise of Recombinant Alternatives

The dependence on voluntary donation makes plasma supply vulnerable to shortages, and the collection, storage, and screening processes add meaningfully to production costs. Recombinant therapies, which do not rely on donor plasma and offer more consistent purity, are emerging as a lower-risk substitute in some treatment areas, creating headwinds for traditional plasma-derived product makers.

How Is Market Segmentation Done?

The research gives an in-depth segmental analysis of the blood plasma industry. The segmentation in the market has been done on the basis of type, application, end-use, and region. This research assesses the contribution of each segment and pinpoints the segments driving the present-day demand and those that will grow strongly during the forecast period. This analysis helps stakeholders analyze evolving demand trends and recognize promising market opportunities.

By Type: Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Others

By Application: Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand's Disease, Others

By End-Use: Hospitals, Clinics, Others

Which Region Leads Market Demand?

The report includes a regional analysis of the blood plasma market, covering North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market dominates the overall market, holding 45.0% share in 2025. North America, led by the United States and Canada, remains a major contributor to global plasma-derived product supply. Its voluntary donation programs and mature fractionation infrastructure allow it to meet both domestic demand and a portion of international needs, particularly during periods of public-health emergency when plasma supply becomes critical. Further, the Asia Pacific market is expected to witness significant growth during the forecast period, registering a CAGR of 8.50%. Government regulations and policies designed to ensure the safety and adequacy of plasma collection are strengthening the market across Asia Pacific. Rising patient awareness and growing R&D activity are increasing demand for plasma-derived therapies, while government-backed donation drives are helping build a steady base of raw material supply.

Who Are the Key Market Players?

The report presents a detailed competitive analysis of the blood plasma industry. Player positioning and their strategy, such as new product/service launches, partnerships, mergers and acquisitions, geographic expansion, capacity expansion, technological developments, etc., have been analyzed. The report also examines the competitive structure of the industry and how organizations are responding to changing consumer demands.

A few of the key players in the market include:

• Biotest AG
• CSL
• GC Biopharma Corp
• Grifols
• Intas Pharmaceuticals Ltd
• Kedrion S.p.A.
• LFB
• Octapharma AG
• Sanquin
• Takeda Pharmaceuticals

Future Outlook

The blood plasma market is projected to keep expanding through 2034 as demand for immunoglobulins and clotting-factor therapies used in immunology, neurology, hematology, and critical care grows alongside the rising prevalence of chronic diseases, autoimmune disorders, and rare genetic conditions. Continued advances in fractionation, purification, and pathogen-reduction technologies are expected to improve product safety and manufacturing efficiency, while expanding healthcare infrastructure in emerging economies and greater public awareness of plasma donation programs should strengthen global collection networks and reinforce blood plasma's role in modern biopharmaceutical manufacturing.

More Trending Latest Reports By Polaris Market Research:

sustainability-as-a-business-driver-how-of-consumers-now-influence-market-strategies

benchmarking-performance-of-the-top-20-companies-in-the-livestock-monitoring-market-in-2025

germanium-market

fruit-and-vegetable-wash-market

biofabrication-market

hydrochloric-acid-market

micro-mobility-market

industrial-hose-market

policosanol-market